Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

Hedy L. Kindler(University of Chicago), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Jaafar Bennouna(Hôpital Foch), Peter C. Trask(Pfizer (United States)), Gregory M. Springett(Moffitt Cancer Center), Sinil Kim(Pfizer (United States)), Junji Furuse(Kanagawa Prefectural Hospital Organization), Harpreet Wasan(Hammersmith Hospital), Takuji Okusaka(National Cancer Centre Japan), Young Suk Park(Samsung Medical Center), Richard Létourneau(Centre Hospitalier de l’Université de Montréal), Shinichi Ohkawa(National Cancer Center Hospital East), Akihiro Funakoshi(National Cancer Center Hospital East), D. J. Richel(Unknown), Paul Bycott(Pfizer (United States)), Alejandro D. Ricart(Pfizer (United States)), Tatsuya Ioka(National Cancer Center Hospital East)
The Lancet Oncology
February 8, 2011
10.1016/s1470-2045(11)70004-3
Cited by 396

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k